Neurophet to unveil AD treatment solution 'Neurophet AQUA AD' at AAIC 2024

Neurophet, a leading AI solution company specializing in brain diseases, is set to participate in the Alzheimer's Association International Conference (AAIC 2024) in Philadelphia, USA. This notable event will see the launch of Neurophet's comprehensive software solution, 'Neurophet AQUA AD,' designed for prescribing and monitoring Alzheimer's disease (AD) treatments.

Neurophet AQUA AD is an advanced software integrating cutting-edge brain image analysis technology, aimed at enhancing the prescription process and monitoring the efficacy and side effects of AD treatments. This innovative solution is currently undergoing medical device certification in Korea, the USA, and Japan.

At their AAIC booth, Neurophet will provide live demonstrations of Neurophet AQUA AD. Additionally, they will showcase an updated version of their brain PET image analysis software, Neurophet SCALE PET, which now includes a centiloid scale feature. This feature quantitatively assesses amyloid PET images, standardizing amyloid plaque deposition from 1 to 100, regardless of the tracer used.

The AD treatment market is poised for significant growth following the FDA's recent approval of Eli Lilly's new AD treatment, Kisunla (donanemab), adding to the existing treatment Leqembi (lecanemab) developed by Eisai and Biogen. Both treatments, however, carry a warning regarding amyloid-related imaging abnormalities (ARIA), side effects that can manifest as edema and microhemorrhages. Clinical trials have reported ARIA in 20-30% of patients on these treatments. Consequently, patients require frequent MRI scans—at least five to six times a year—to monitor ARIA.

Neurophet AQUA AD offers a comprehensive solution by providing all necessary brain imaging biomarker analysis features for the administration of anti-amyloid treatments. It quantitatively analyzes MRI and PET images, helping determine patient eligibility for treatment, monitoring ARIA during treatment, and assessing the treatment's effectiveness by measuring the reduction of amyloid beta deposits in the brain.

Moreover, the updated Neurophet SCALE PET with the centiloid scale feature is a significant advancement. This feature allows for a standardized evaluation of amyloid plaque deposits in amyloid PET images, ensuring consistency even when different tracers are used.

"We are thrilled to introduce our groundbreaking total solution for AD treatments at AAIC, a premier global conference that brings together scholars from around the world," stated Jake Junkil Been, CEO of Neurophet. "We anticipate that Neurophet AQUA AD, with its specialized brain image analysis technology for AD treatments, will be widely adopted."

The AAIC is the world's largest conference dedicated to advancing dementia research, bringing together researchers, clinicians, and professionals to share insights on diagnosis, risk reduction, and treatment improvements for AD and other dementias. This year's conference, held in Philadelphia, USA, runs from July 28th to August 1st.

Neurophet, founded in 2016 by CEO Jake Junkil Been and CTO Donghyeon Kim, specializes in developing AI-based solutions for diagnosing and treating brain diseases. Their product lineup includes the brain MRI analysis software "Neurophet AQUA," the brain PET image analysis software "Neurophet SCALE PET," and the brain imaging treatment planning software for electric and magnetic brain stimulation, "Neurophet tES/TMS LAB."

Neurophet remains committed to aiding patients with brain diseases, leveraging their expertise in neuroscience to explore brain health and pioneer AI-based solutions for brain disorders.